Treatment with intravenous (IV) or subcutaneous (SC) administration of recombinant human IL-15 (rhIL-15) is associated with an antileukemic effect when combined with lymphodepleting chemotherapy and haplo-NK-cell infusion and caused CR in 35% of patients, demonstrating the importance of NK cells in harnessing an immune response against AML [128]. This evidence concerns the gene IL15 and acute myeloid leukemia.